Since the RelA T505 residue can be phosphorylated by the checkpoint kinase CHK1 [17], we next determined whether the RelA T505A mutation would also affect cell survival in response to treatment with CHK1 inhibitors, an important class of novel cancer therapeutics currently in clinical trials [28]. Here, CHEK1 is linked to cancer.